Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?
Jhaveri K, Ulaner GA, Dickler MN. Jhaveri K, et al. J Clin Oncol. 2015 Aug 20;33(24):2591-3. doi: 10.1200/JCO.2015.62.3082. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195716 No abstract available.
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.
Jhaveri K, Chandarlapaty S, Iyengar N, Morris PG, Corben AD, Patil S, Akram M, Towers R, Sakr RA, King TA, Norton L, Rosen N, Hudis C, Modi S. Jhaveri K, et al. Clin Breast Cancer. 2016 Aug;16(4):276-83. doi: 10.1016/j.clbc.2015.11.004. Epub 2015 Nov 19. Clin Breast Cancer. 2016. PMID: 26726007 Free PMC article.
Molecular Imaging of Biomarkers in Breast Cancer.
Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W. Ulaner GA, et al. Among authors: jhaveri k. J Nucl Med. 2016 Feb;57 Suppl 1(Suppl 1):53S-9S. doi: 10.2967/jnumed.115.157909. J Nucl Med. 2016. PMID: 26834103 Free PMC article. Review.
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.
Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. Ulaner GA, et al. Among authors: jhaveri k. J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16. J Nucl Med. 2018. PMID: 29146695 Free PMC article. Clinical Trial.
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF. Paoletti C, et al. Among authors: jhaveri k. Clin Cancer Res. 2018 Dec 1;24(23):5860-5872. doi: 10.1158/1078-0432.CCR-18-1569. Epub 2018 Aug 6. Clin Cancer Res. 2018. PMID: 30082476 Clinical Trial.
512 results